HRP20140266T1 - Postupci inhibiranja vezanja endosijalina na ligande - Google Patents

Postupci inhibiranja vezanja endosijalina na ligande Download PDF

Info

Publication number
HRP20140266T1
HRP20140266T1 HRP20140266AT HRP20140266T HRP20140266T1 HR P20140266 T1 HRP20140266 T1 HR P20140266T1 HR P20140266A T HRP20140266A T HR P20140266AT HR P20140266 T HRP20140266 T HR P20140266T HR P20140266 T1 HRP20140266 T1 HR P20140266T1
Authority
HR
Croatia
Prior art keywords
antibody
antigen
binding fragment
seq
intended
Prior art date
Application number
HRP20140266AT
Other languages
English (en)
Inventor
Yuhong Zhou
Brian E. Tomkowicz
Luigi Grasso
Philip M. Sass
Nicholas C. Nicolaides
Original Assignee
Morphotek, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek, Inc. filed Critical Morphotek, Inc.
Publication of HRP20140266T1 publication Critical patent/HRP20140266T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (10)

1. Protutijelo, ili njegov antigenski vežući fragment, koje se specifično veže na endosijalin i koje inhibira međudjelovanje između endosijalina eksprimiranog na površini stanice i kolagena ili fibronektina, naznačeno time što je namijenjeno upotrebi u inhibiranju neovaskularizacije ili angiogeneze u novotvorini kod subjekta.
2. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što se navedeno protutijelo, ili njegov antigenski vežući fragment, ne veže na mišji endosijalin.
3. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je vrijednost afiniteta vezanja navedenog protutijela, ili njegovog antigenski vežućeg fragmenta, na endosijalin manja od 1 x 10 M–7.
4. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je navedeno protutijelo, ili njegov antigenski vežući fragment, kimerno protutijelo, ili njegov antigenski vežući fragment, ili je humanizirano protutijelo, ili njegov antigenski vežući fragment.
5. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što protutijelo, ili njegov antigenski vežući fragment, sadrži teški lanac, koji sadrži CDR1 sa SEQ ID NO:28, CDR2 sa SEQ ID NO:30 i CDR3 sa SEQ ID NO:32, i laki lanac, koji sadrži CDR1 sa SEQ ID NO:13, CDR2 sa SEQ ID NO:15 i CDR3 sa SEQ ID NO:17.
6. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što protutijelo, ili njegov antigenski vežući fragment, sadrži teški lanac, koji sadrži varijabilnu domenu sa SEQ ID NO: 34, i laki lanac, koji sadrži varijabilnu domenu sa SEQ ID NO: 19.
7. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačeno time što protutijelo, ili njegov antigenski vežući fragment, sadrži teški lanac, koji sadrži aminokiselinski slijed sa SEQ ID NO:22 ili 26, i laki lanac, koji sadrži aminokiselinski slijed sa SEQ ID NO:11.
8. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što protutijelo proizvode stanice s ATCC pristupnim brojem PTA-7554 ili ATCC pristupni broj PTA-9017.
9. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što navedena stanica jest stanica sisavca.
10. Protutijelo, ili njegov antigenski vežući fragment, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što je navedena stanica neoplastična stanica.
HRP20140266AT 2007-04-05 2014-03-20 Postupci inhibiranja vezanja endosijalina na ligande HRP20140266T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91036207P 2007-04-05 2007-04-05
US98002607P 2007-10-15 2007-10-15
PCT/US2008/059374 WO2008124570A1 (en) 2007-04-05 2008-04-04 Methods for inhibiting the binding of endosialin to ligands

Publications (1)

Publication Number Publication Date
HRP20140266T1 true HRP20140266T1 (hr) 2014-04-25

Family

ID=39714208

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20140266AT HRP20140266T1 (hr) 2007-04-05 2014-03-20 Postupci inhibiranja vezanja endosijalina na ligande
HRP20161715TT HRP20161715T1 (hr) 2007-04-05 2016-12-14 Postupci inhibiranja vezanja endosijalina na ligande

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20161715TT HRP20161715T1 (hr) 2007-04-05 2016-12-14 Postupci inhibiranja vezanja endosijalina na ligande

Country Status (20)

Country Link
US (4) US7807382B2 (hr)
EP (2) EP2620451B1 (hr)
JP (2) JP5825784B2 (hr)
KR (1) KR101529334B1 (hr)
CN (1) CN101918446B (hr)
AU (1) AU2008237296B2 (hr)
BR (1) BRPI0809665B8 (hr)
CA (1) CA2682726C (hr)
CY (2) CY1115370T1 (hr)
DK (2) DK2137217T3 (hr)
ES (2) ES2606906T3 (hr)
HR (2) HRP20140266T1 (hr)
HU (1) HUE031269T2 (hr)
LT (1) LT2620451T (hr)
MX (1) MX2009010701A (hr)
PL (2) PL2137217T3 (hr)
PT (2) PT2620451T (hr)
RS (2) RS55447B1 (hr)
SI (2) SI2137217T1 (hr)
WO (1) WO2008124570A1 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538700A (ja) * 2005-04-22 2008-11-06 モルフォテック、インク． 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
DK2137217T3 (en) * 2007-04-05 2014-03-17 Morphotek Inc Methods of inhibiting the binding of endosialin to ligands
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
US20100260769A1 (en) * 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
EP2621946A1 (en) 2010-09-29 2013-08-07 Morphotek, Inc. Engineered human endosialin-expressing rodents
EP2831114B1 (en) 2012-03-30 2019-05-08 Eisai R&D Management Co., Ltd. Tem-1 diagnostic antibodies
WO2013162748A1 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (tem1) antibody variants and uses thereof
EP2964764A1 (en) 2013-03-09 2016-01-13 Baylor College Of Medicine Vascular-targeted t-cell therapy
GB201702926D0 (en) * 2017-02-23 2017-04-12 Univ Birmingham Modulators
MX2020001057A (es) 2017-07-28 2020-11-24 Applied Therapeutics Inc Composiciones y metodos para tratar la galactosemia.
CN110531077B (zh) * 2018-05-25 2023-07-07 荣昌生物制药(烟台)股份有限公司 间皮素免疫组化检测试剂盒
CN111026023A (zh) * 2020-01-12 2020-04-17 安徽楚江科技新材料股份有限公司 基于s7-400控制系统的铜带轧机PLC组态方法
CN116790744B (zh) * 2023-06-30 2024-04-26 浙江大学 一种缺血性心脏病晚期纤维化干预靶点及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5342757A (en) 1992-11-13 1994-08-30 Ludwig Institute For Cancer Research Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof
ATE244888T1 (de) 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
DK0746613T3 (da) 1994-03-08 2006-09-25 Sloan Kettering Inst Cancer Rekombinante humaniserede antistoffer mod FB5
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6146894A (en) 1998-04-14 2000-11-14 The Johns Hopkins University Method for generating hypermutable organisms
CA2355337A1 (en) 1998-09-09 2000-03-16 U.S. Army Institute Of Surgical Research Method for monitoring arterial oxygen saturation
AU2001248352A1 (en) 2000-03-15 2001-09-24 Epigenomics Ag Diagnosis of diseases associated with the cell cycle
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
ATE501635T1 (de) 2001-01-15 2011-04-15 Morphotek Inc Chemische hemmstoffe des mismatch-repair
US20040043928A1 (en) 2001-08-02 2004-03-04 Ramesh Kekuda Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030124579A1 (en) 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040014058A1 (en) 2001-10-05 2004-01-22 Alsobrook John P. Novel human proteins, polynucleotides encoding them and methods of using the same
US20060127902A1 (en) 2002-08-15 2006-06-15 Genzyme Corporation Brain endothelial cell expression patterns
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
EP2267031A1 (en) 2003-03-04 2010-12-29 Kirin Beer Kabushiki Kaisha Endothelial cell specific antibodies and uses thereof
WO2005086713A2 (en) * 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
WO2006029045A2 (en) 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
EP1793868B1 (en) 2004-09-23 2010-12-29 Guerbet Liposomal contrast agents for cest imaging
WO2006060719A2 (en) 2004-12-03 2006-06-08 Morphotek, Inc. Use of endosialin binding proteins to isolate endosialin positive cells
EP1856278A2 (en) 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
JP2008538700A (ja) 2005-04-22 2008-11-06 モルフォテック、インク． 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体
US7315372B1 (en) * 2005-09-29 2008-01-01 The United States Of America As Represented By The Secretary Of The Navy Instrument using near-field intensity correlation measurements for characterizing scattering of light by suspensions
DE102005050933A1 (de) 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US7908090B2 (en) 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
JP2009523709A (ja) 2005-12-16 2009-06-25 ジェネンテック・インコーポレーテッド 神経膠腫の診断、予後の予測及び治療の方法
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
WO2008006517A2 (en) 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
EP2049713A4 (en) 2006-07-21 2010-06-16 Univ Alberta TISSUE REJECTION
WO2008021288A2 (en) 2006-08-11 2008-02-21 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US20080300170A1 (en) 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US20110119776A1 (en) 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
EP1986010A1 (en) 2007-04-05 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and tools for discriminating colorectal adenomas and adenocarcinomas
DK2137217T3 (en) * 2007-04-05 2014-03-17 Morphotek Inc Methods of inhibiting the binding of endosialin to ligands
JP5769417B2 (ja) 2007-08-16 2015-08-26 ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ 腫瘍細胞由来微小胞
CN102084000B (zh) 2008-02-01 2016-03-16 总医院有限公司 微泡在医学疾病和病况的诊断、预后以及治疗中的用途
WO2009105549A2 (en) 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer
WO2009120877A2 (en) 2008-03-26 2009-10-01 The Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
WO2010045714A1 (en) 2008-10-20 2010-04-29 University Health Network Methods and compositions for the detection of ovarian cancer
AU2010204741B2 (en) 2009-01-14 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
US20100260769A1 (en) 2009-04-09 2010-10-14 Morphotek, Inc. Endosialin binding molecules

Also Published As

Publication number Publication date
US8895000B2 (en) 2014-11-25
MX2009010701A (es) 2010-01-20
HUE031269T2 (en) 2017-06-28
PL2137217T3 (pl) 2014-08-29
EP2137217B1 (en) 2014-03-05
SI2137217T1 (sl) 2014-07-31
CN101918446A (zh) 2010-12-15
DK2137217T3 (en) 2014-03-17
US20170029509A1 (en) 2017-02-02
EP2620451A1 (en) 2013-07-31
CN101918446B (zh) 2014-06-18
RS55447B1 (sr) 2017-04-28
KR20100016221A (ko) 2010-02-12
KR101529334B1 (ko) 2015-06-16
JP2013150618A (ja) 2013-08-08
US9505842B2 (en) 2016-11-29
US20150079104A1 (en) 2015-03-19
BRPI0809665B8 (pt) 2021-05-25
LT2620451T (lt) 2017-01-10
RS53362B (en) 2014-10-31
HRP20161715T1 (hr) 2017-02-10
BRPI0809665B1 (pt) 2021-03-23
JP2010523592A (ja) 2010-07-15
SI2620451T1 (sl) 2017-01-31
WO2008124570A1 (en) 2008-10-16
US20110033455A1 (en) 2011-02-10
ES2606906T3 (es) 2017-03-28
CA2682726C (en) 2017-05-09
BRPI0809665A2 (pt) 2018-12-04
DK2620451T3 (da) 2017-01-02
CA2682726A1 (en) 2008-10-16
WO2008124570A8 (en) 2008-11-27
ES2452929T3 (es) 2014-04-03
EP2620451B1 (en) 2016-09-14
PL2620451T3 (pl) 2017-06-30
CY1118592T1 (el) 2017-07-12
PT2137217E (pt) 2014-03-20
AU2008237296A1 (en) 2008-10-16
US20080248034A1 (en) 2008-10-09
JP5825784B2 (ja) 2015-12-02
CY1115370T1 (el) 2017-01-04
AU2008237296B2 (en) 2013-07-04
US10053509B2 (en) 2018-08-21
EP2137217A1 (en) 2009-12-30
US7807382B2 (en) 2010-10-05
PT2620451T (pt) 2016-12-20

Similar Documents

Publication Publication Date Title
HRP20140266T1 (hr) Postupci inhibiranja vezanja endosijalina na ligande
HRP20200090T1 (hr) Monoklonska protutijela protiv receptora 2 čimbenika rasta fibroblasta
RU2017128882A (ru) Антитела к биотину и способы их применения
IL265179B2 (en) Antibodies against PD-1 (CD27)
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
HRP20151213T1 (hr) Anti-c5a protutijela i postupci za uporabu protutijela
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
JP2012502649A5 (hr)
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
HRP20180776T1 (hr) Antagonisti il17c za liječenje upalnih poremećaja
HRP20131215T1 (hr) Antagonistiäśka humana monoklonska protutijela specifiäśna za humane slabe epitope
RS52860B (en) ANTI-ILT7 ANTITELO
RS53263B (en) CD19 OPTIMIZED ANTIBODY
PE20120835A1 (es) Anticuerpos anti-tnf-alfa y sus usos
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RS52176B (en) HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
RU2008129111A (ru) Антитела к ox40l и способы их применения
HRP20230411T1 (hr) Dvostruko ciljanje
NZ599497A (en) Humanized antibodies to amyloid beta
JP2010523592A5 (hr)
RU2013140350A (ru) Антитела против человеческого il33r и их применение